Cargando…

Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis

BACKGROUND: Although androgen deprivation therapy has known cardiovascular risks, it is unclear if its duration is related to cardiovascular risks. This study thus aimed to investigate the associations between gonadotrophin‐releasing hormone (GnRH) agonist use duration and cardiovascular risks. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Jeffrey S. K., Tang, Pias, Hui, Jeremy M. Ho, Lee, Yan H. A., Dee, Edward C., Ng, Kenrick, Liu, Kang, Tse, Gary, Ng, Chi Fai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804360/ https://www.ncbi.nlm.nih.gov/pubmed/35915869 http://dx.doi.org/10.1002/pros.24423

Ejemplares similares

Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders
por: Xia, Min, et al.
Publicado: (2021)

Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
por: Chung, Seung Ah, et al.
Publicado: (2021)

The effect of gonadotrophin-releasing hormone agonist versus human chorionic gonadotrophin trigger on pregnancy and neonatal outcomes in Letrozole-HMG IUI cycles
por: Chen, Li, et al.
Publicado: (2023)

Gonadotrophin releasing hormone antagonist in IVF/ICSI
por: MS, Kamath, et al.
Publicado: (2008)

Review of Implant Gonadotrophin-Releasing Hormone Agonist Use: Experience in a Single Academic Center
por: Ni, Jennifer, et al.
Publicado: (2023)

Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer
por: Teoh, Jeremy YC, et al.
Publicado: (2015)

Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based study
por: Lee, Yan Hiu Athena, et al.
Publicado: (2022)

Comparison of estrogen receptor-α, progesterone receptor and calponin expression in gonadotrophin-releasing hormone agonist-sensitive and -resistant uterine fibroids
por: Kim, Eun Hee, et al.
Publicado: (2014)

Evaluation of adenomyosis after gonadotrophin-releasing hormone agonist therapy using ultrasound post-processing imaging: a pilot study
por: Chou, Szu-Yuan, et al.
Publicado: (2020)

Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2023)

Using automated imaging to interrogate gonadotrophin-releasing hormone receptor trafficking and function
por: Armstrong, S.P., et al.
Publicado: (2011)

Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists
por: Fragkoulis, Charalampos, et al.
Publicado: (2021)

HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2022)

Effectiveness of gonadotrophin-releasing hormone agonist therapy to improve the outcomes of intrauterine insemination in patients suffering from stage I-II endometriosis
por: Zhang, Kemei, et al.
Publicado: (2022)

Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population‐based cohort study
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2023)

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK
por: Rosario, Derek J., et al.
Publicado: (2016)

Gonadotrophin-releasing hormone agonist-induced pituitary adenoma apoplexy and casual finding of a parathyroid carcinoma: A case report and review of literature
por: Triviño, Vanessa, et al.
Publicado: (2019)

Temporal and Spatial Regulation of CRE Recombinase Expression in Gonadotrophin-Releasing Hormone Neurones in the Mouse
por: Wolfe, A, et al.
Publicado: (2008)

Antibodies Against Gonadotropin-Releasing Hormone in Patients with Posterior Laryngitis
por: Pendleton, Hillevi, et al.
Publicado: (2013)

Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study
por: Chan, Raymond Ngai Chiu, et al.
Publicado: (2022)

The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors.
por: Qayum, A., et al.
Publicado: (1990)

Gonadotrophin stimulation and risk of relapse in breast cancer
por: Fredriksson, A, et al.
Publicado: (2021)

Metformin use and hospital attendance‐related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based cohort study
por: Lee, Yan Hiu Athena, et al.
Publicado: (2023)

Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts
por: Jacobs, E, et al.
Publicado: (1999)

Research Note: Polymorphisms of gonadotrophin-releasing hormone gene and their association with growth traits in quail (Coturnix Coturnix)
por: Wang, Xinle, et al.
Publicado: (2022)

Effects of follicle‐stimulating hormone followed by gonadotropin‐releasing hormone on embryo production by ovum pick‐up and in vitro fertilization in the river buffalo (Bubalus bubalis)
por: Sakaguchi, Kenichiro, et al.
Publicado: (2019)

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022)

Gonadotrophins: The future
por: Patil, Madhuri
Publicado: (2014)

Plasmid DNA vaccine coding eight repeats of gonadotrophin-releasing hormone induced atrophy of prostate in male mice
por: Rima, Umme K., et al.
Publicado: (2018)

Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women
por: Bahaeldein, E, et al.
Publicado: (2018)

Interplay between nitric oxide and gonadotrophin-releasing hormone in the neuromodulation of the corpus luteum during late pregnancy in the rat
por: Vallcaneras, Sandra, et al.
Publicado: (2022)

Optimizing estradiol level for gonadotrophin-releasing hormone antagonist initiation among patients with simple tubal factor infertility
por: Wang, Yizhuo, et al.
Publicado: (2022)

The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments
por: Anckaert, Ellen, et al.
Publicado: (2012)

Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population‐based cohort study
por: Lee, Yan Hiu Athena, et al.
Publicado: (2023)

Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022)

Using learning analytics in clinical competency committees: Increasing the impact of competency-based medical education
por: Carney, Patricia A., et al.
Publicado: (2023)

Subcutaneous infusion of kisspeptin‐54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels
por: Narayanaswamy, Shakunthala, et al.
Publicado: (2015)

Gonadotrophin-Releasing Hormone (GnRH) Analogues in the Treatment of Mixed Mullerian Tumours of the Uterus: Two Case Reports and Review
por: Katesmark, Michael, et al.
Publicado: (1998)

The correlation of anandamide with gonadotrophin and sex steroid hormones during the menstrual cycle
por: Cui, Na, et al.
Publicado: (2017)

Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2aodfj15df3763gd8n0svssg6p